Figure 5

The immune characteristics of different MRS patient subgroups. (A) CIBERSORT analyses were used to assess immune cell infiltration in the indicated MRS subgroups. (B) ssGSEA analyses were used to assess immune cell-related gene expression in the indicated MRS subgroups. (C–F) Analyses of the relationship between MRS scores and stromal score (C), immune score (D), estimate score (E), and tumor purity (F). (G,H) The association between MRS subgroups and the expression of immune checkpoint genes. (I) The relationship between MRS subgroups and predicted immunotherapy outcomes. (J–L) The relationship between different MRS subgroups and predicted treatment outcomes for CTLA4 (J), PD-1 (K), or CTLA4 + PD-1 (L) targeted treatments. *P < 0.05; **P < 0.01; ***P < 0.001.